Ciclosporin ophthalmic - Novaliq

Drug Profile

Ciclosporin ophthalmic - Novaliq

Alternative Names: CyclASol; CyclAsol; Cyclosol; Cyclosporine; Cyclosporine-A

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novaliq
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Neuroprotectants
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Dry eyes

Most Recent Events

  • 19 Oct 2017 Phase-II/III clinical trials in Dry eyes in USA (Ophthalmic) (NCT03292809)
  • 04 Oct 2017 Novaliq plans a phase II/III trial for Dry eyes (NCT03292809)
  • 05 Jan 2017 Top-line safety and efficacy results from the phase II trial in Dry eyes released by Novaliq
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top